围移植期芦可替尼治疗骨髓纤维化安全有效:一项开放标签先导研究
该前瞻性先导试验评估围移植期芦可替尼治疗骨髓纤维化的安全性与最大耐受剂量。早期疗效在高危老年患者中极具前景。
要点
- 围移植期芦可替尼最大耐受剂量为10mg每日两次
- 所有患者均成功植入,1年总生存率77%
- 急性GVHD 2-4级和3-4级累积发生率分别为17%和11%
核心结论
- 围移植期芦可替尼在最大耐受剂量10mg每日两次下安全且耐受良好,并呈现剂量依赖性药代动力学和细胞因子谱。
- 在高危老年骨髓纤维化患者中,早期疗效数据极具前景。
研究设计与样本
- 前瞻性先导开放标签试验,评估围移植期芦可替尼治疗骨髓纤维化的安全性和可行性。
- 主要目标为确定安全性和最大耐受剂量,芦可替尼设5mg和10mg每日两次两个剂量水平。
- 预处理方案为氟达拉滨/美法仑,GVHD预防为他克莫司/西罗莫司。
- 移植中位年龄65岁(范围25-73),按DIPSS评分4例高危、14例中危。
主要发现
- 每个剂量水平各有1例患者出现剂量限制性毒性:剂量水平1为3级心脏和胃肠道毒性伴4级肺毒性,剂量水平2为3级肾损伤。
- 所有患者均实现植入。
- 2-4级和3-4级急性GVHD累积发生率分别为17%(95%CI 6-47)和11%(95%CI 3-41)。
- 1年慢性GVHD累积发生率为42%(95%CI 24-74)。
- 存活患者中位随访22.6个月(范围6.2-25.8),1年总生存率和无进展生存率分别为77%(95%CI 50-91)和71%(95%CI 44-87)。
关键数值与推荐
- 最大耐受剂量为芦可替尼10mg每日两次。
- 剂量水平1(5mg每日两次)和剂量水平2(10mg每日两次)各观察到1例剂量限制性毒性。
- 1年总生存率77%(95%CI 50-91),1年无进展生存率71%(95%CI 44-87)。
- 2-4级急性GVHD累积发生率17%(95%CI 6-47),3-4级为11%(95%CI 3-41)。
- 1年慢性GVHD累积发生率42%(95%CI 24-74)。
临床怎么用
- 围移植期芦可替尼10mg每日两次可作为骨髓纤维化移植患者的可行选择,需关注剂量限制性毒性。
- 治疗期间应监测心脏、胃肠道、肺和肾脏毒性。
- 该方案在高危老年骨髓纤维化患者中显示出有前景的早期生存获益。
局限性
- 非随机设计,缺乏对照組。
- 随访时间有限,存活患者中位随访22.6个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report results of our prospective pilot trial evaluating safety/feasibility of peritransplantation ruxolitinib for myelofibrosis treatment. Primary objectives were to determine safety and maximum tolerated dose (MTD) of ruxolitinib. Ruxolitinib was administered at 2 dose levels (DLs) of 5 and 10 mg twice daily, with fludarabine/melphalan conditioning regimen and tacrolimus/sirolimus graft-versus-host disease (GVHD) prophylaxis. We enrolled 6 and 12 patients at DL1 and DL2, respectively. Median age at transplantation was 65 years (range, 25-73). Per Dynamic International Prognostic Scoring System, 4 patients were high and 14 intermediate risk. Peripheral blood stem cells were graft source from matched sibling (n = 5) or unrelated (n = 13) donor. At each DL, 1 patient developed dose-limiting toxicities (DLTs): grade 3 cardiac and gastrointestinal with grade 4 pulmonary DLTs in DL1, and grade 3 kidney injury in DL2. All patients achieved engraftment. Grade 2 to 4 and 3 to 4 acute GVHD cumulative incidence was 17% (95% confidence interval [CI], 6-47) and 11% (95% CI, 3-41), respectively. Cumulative incidence of 1-year chronic GVHD was 42% (95% CI, 24-74). With 22.6-month (range, 6.2-25.8) median follow-up in surviving patients, 1-year overall and progression-free survival were 77% (95% CI, 50-91) and 71% (95% CI, 44-87), respectively. Causes of death (n = 4) were cardiac arrest, GVHD, respiratory failure, and refractory GVHD of liver. Our results show peritransplantation ruxolitinib is safe and well tolerated at MTD of 10 mg twice daily and associated with dose-dependent pharmacokinetic and cytokine profile. Early efficacy data are highly promising in high-risk older patients with myelofibrosis. This trial was registered at www.clinicaltrials.gov as #NCT02917096.
引用
- Ali H, Tsai NC, Synold T, et al. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Adv. 2022. PMID: 34581764. doi:10.1182/bloodadvances.2021005035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。